Literature DB >> 27637349

Risk factors and treatment for recurrent vulvar squamous cell carcinoma.

L S Nooij1, F A M Brand1, K N Gaarenstroom1, C L Creutzberg2, J A de Hullu3, M I E van Poelgeest4.   

Abstract

Recurrent disease occurs in 12-37% of patients with vulvar squamous cell carcinoma (VSCC). Decisions about treatment of recurrent VSCC mainly depend on the location of the recurrence and previous treatment, resulting in individualized and consensus-based approaches. Most recurrences (40-80%) occur within 2 years after initial treatment. Currently, wide local excision is the treatment of choice for local recurrences. Isolated local recurrence of VSCC has a good prognosis, with reported 5-year survival rates of up to 60%. Groin recurrences and distant recurrences are less common and have an extremely poor prognosis. For groin recurrences, surgery with or without (chemo) radiotherapy is a treatment option, depending on prior treatment. For distant recurrences, there are only palliative treatment options. In this review, we give an overview of the available literature and discuss epidemiology, risk factors, and prognostic factors for the different types of recurrent VSCC and we describe treatment options and clinical outcome.
Copyright © 2016 The Author(s). Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Recurrence; Risk factors; Squamous cell carcinoma; Treatment; Vulva

Mesh:

Year:  2016        PMID: 27637349     DOI: 10.1016/j.critrevonc.2016.07.007

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  16 in total

1.  Human Papillomavirus‒Positive and ‒Negative Vulvar Squamous Cell Carcinoma Are Biologically but Not Clinically Distinct.

Authors:  Elysha Kolitz; Elena Lucas; Gregory A Hosler; Jiwoong Kim; Suntrea Hammer; Cheryl Lewis; Lin Xu; Andrew T Day; Melissa Mauskar; Jayanthi S Lea; Richard C Wang
Journal:  J Invest Dermatol       Date:  2021-10-28       Impact factor: 7.590

2.  Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status.

Authors:  Tjalling Bosse; Lynn N Hoang; Basile Tessier-Cloutier; Kim E Kortekaas; Emily Thompson; Jennifer Pors; Julia Chen; Julie Ho; Leah M Prentice; Melissa K McConechy; Christine Chow; Lily Proctor; Jessica N McAlpine; David G Huntsman; C Blake Gilks
Journal:  Mod Pathol       Date:  2020-03-20       Impact factor: 7.842

3.  Prognostic impact of reduced tumor-free margin distance on long-term survival in FIGO stage IB/II vulvar squamous cell carcinoma.

Authors:  Leonardo Micheletti; Mario Preti; Viviana Cintolesi; Elisabetta Corvetto; Silvana Privitera; Eleonora Palmese; Chiara Benedetto
Journal:  J Gynecol Oncol       Date:  2018-04-13       Impact factor: 4.401

4.  The efficacy of ultrasound in the follow up after a negative sentinel lymph node in women with vulvar cancer: a prospective single-centre study.

Authors:  A W Pouwer; Rdm Mus; J IntHout; Agj van der Zee; J Bulten; Lfag Massuger; J A de Hullu
Journal:  BJOG       Date:  2018-08-01       Impact factor: 6.531

5.  Oxymatrine Inhibits Proliferation and Migration of Vulvar Squamous Cell Carcinoma Cells via Attenuation of the RAS/RAF/MEK/ERK Pathway.

Authors:  Yanshi Wang; Shaojie Yang; Shanshan Zhang; Xin Wu
Journal:  Cancer Manag Res       Date:  2020-03-19       Impact factor: 3.989

6.  Practical Guidance for Measuring and Reporting Surgical Margins in Vulvar Cancer.

Authors:  Kim E Kortekaas; Koen K Van de Vijver; Mariëtte I E van Poelgeest; C Blake Gilks; Vincent T H B M Smit; Saimah Arif; Deep Arora; Asma Faruqi; Raji Ganesan; Nicholas R Griffin; Richard Hale; Yelin E Hock; Lars-Christian Horn; W Glenn McCluggage; Pinias Mukonoweshuro; Kay J Park; Brian Rous; Bruce Tanchel; Anne-Sophie Van Rompuy; Gerry van Schalkwyk; Jo Vella; Marco Vergine; Naveena Singh; Tjalling Bosse
Journal:  Int J Gynecol Pathol       Date:  2020-09       Impact factor: 3.326

Review 7.  Image-Guided Brachytherapy for Salvage Reirradiation: A Systematic Review.

Authors:  Sophie Bockel; Sophie Espenel; Roger Sun; Isabelle Dumas; Sébastien Gouy; Philippe Morice; Cyrus Chargari
Journal:  Cancers (Basel)       Date:  2021-03-11       Impact factor: 6.639

8.  Treatment Outcomes of Patients with Squamous Cell Carcinoma of the Vulva: The Largest Series from a Tertiary Care Hospital.

Authors:  Panida Meelapkij; Prapaporn Suprasert; Orthai Baisai
Journal:  Obstet Gynecol Int       Date:  2018-09-03

Review 9.  Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology.

Authors:  Pavol Zubor; Yun Wang; Alena Liskova; Marek Samec; Lenka Koklesova; Zuzana Dankova; Anne Dørum; Karol Kajo; Dana Dvorska; Vincent Lucansky; Bibiana Malicherova; Ivana Kasubova; Jan Bujnak; Milos Mlyncek; Carlos Alberto Dussan; Peter Kubatka; Dietrich Büsselberg; Olga Golubnitschaja
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

10.  Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets.

Authors:  Erik A Williams; Adrienne J Werth; Radwa Sharaf; Meagan Montesion; Ethan S Sokol; Dean C Pavlick; Molly McLaughlin-Drubin; Rachel Erlich; Helen Toma; Kevin Jon Williams; Jeff M Venstrom; Brian M Alexander; Nikunj Shah; Natalie Danziger; Amanda C Hemmerich; Eric A Severson; Jonathan Keith Killian; Douglas I Lin; Jeffrey S Ross; Julie Y Tse; Shakti H Ramkissoon; Mark C Mochel; Julia A Elvin
Journal:  JCO Precis Oncol       Date:  2020-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.